Beigene Ltd
SSE:688235
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
102.01
191
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Beigene Ltd
Beigene Ltd
Cash from Operating Activities
Beigene Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Beigene Ltd
SSE:688235
|
Cash from Operating Activities
-¥7.8B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Tanvex BioPharma Inc
TWSE:6541
|
Cash from Operating Activities
-NT$1.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Polaris Group
TWSE:6550
|
Cash from Operating Activities
-NT$1.3B
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
Beigene Ltd
Glance View
Beigene Ltd., a globally recognized biotechnology company, has emerged as a significant player in the fight against cancer through its innovative treatments and robust pipeline of therapies. Founded in 2010, the company has its roots in China and quickly expanded its presence within the international oncology market, focusing on the discovery, development, and commercialization of medicines to treat cancer. Beigene is particularly known for its groundbreaking drug, Brukinsa (zanubrutinib), which targets specific malignancies and has garnered approval across various jurisdictions, including the U.S. and China. This strategic focus on precision medicine not only positions Beigene at the forefront of cancer treatment advancements but also highlights its commitment to addressing unmet medical needs. Investors looking at Beigene Ltd. can appreciate its aggressive growth trajectory and strategic collaborations with leading pharmaceutical companies, which enhance its R&D capabilities and market reach. The company’s upcoming product launches and ongoing clinical trials present considerable opportunities for revenue generation. Additionally, with a strong balance sheet and a vision to alleviate the global cancer burden, Beigene is not just advancing science; it's actively contributing to the well-being of patients worldwide. As the global healthcare landscape evolves, Beigene's innovation-driven approach and commitment to quality position it as a promising investment in the ever-expanding biopharmaceutical sector.
See Also
What is Beigene Ltd's Cash from Operating Activities?
Cash from Operating Activities
-7.8B
CNY
Based on the financial report for Dec 31, 2023, Beigene Ltd's Cash from Operating Activities amounts to -7.8B CNY.
What is Beigene Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-13%
Over the last year, the Cash from Operating Activities growth was 0%. The average annual Cash from Operating Activities growth rates for Beigene Ltd have been -15% over the past three years , -13% over the past five years .
You don't have any saved screeners yet
